Literature DB >> 24349887

Differential Role of Two-Component Regulatory Systems (phoPQ and pmrAB) in Polymyxin B Susceptibility of Pseudomonas aeruginosa.

Daniel Owusu-Anim1, Dong H Kwon2.   

Abstract

Polymyxins are often considered as a last resort to treat multidrug resistant P. aeruginosa but polymyxin resistance has been increasingly reported worldwide in clinical isolates. Polymyxin resistance in P. aeruginosa is known to be associated with alterations in either PhoQ or PmrB. In this study, mutant strains of P. aeruginosa carrying amino acid substitution, a single and/or dual inactivation of PhoQ and PmrB were constructed to further understand the roles of PhoQ and PmrB in polymyxin susceptibility. Polymyxin B resistance was caused by both inactivation and/or amino acid substitutions in PhoQ but by only amino acid substitutions of PmrB. Alterations of both PhoQ and PmrB resulted in higher levels of polymyxin B resistance than alteration of either PhoQ or PmrB alone. These results were confirmed by time-killing assays suggesting that high-level polymyxin resistance in P. aeruginosa is caused by alterations of both PhoQ and PmrB.

Entities:  

Keywords:  Polymyxin B Resistance; Pseudomonas aeruginosa; phoPQ; pmrAB

Year:  2012        PMID: 24349887      PMCID: PMC3859615          DOI: 10.4236/aim.2012.21005

Source DB:  PubMed          Journal:  Adv Microbiol        ISSN: 2165-3402


  25 in total

1.  Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.

Authors:  Matthew E Falagas; Petros I Rafailidis; Dimitrios K Matthaiou; Simona Virtzili; Dimitra Nikita; Argyris Michalopoulos
Journal:  Int J Antimicrob Agents       Date:  2008-09-02       Impact factor: 5.283

2.  Polyamines induce resistance to cationic peptide, aminoglycoside, and quinolone antibiotics in Pseudomonas aeruginosa PAO1.

Authors:  Dong H Kwon; Chung-Dar Lu
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline.

Authors:  Catharine A Trieber; Diane E Taylor
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

4.  Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.

Authors:  David Landman; Simona Bratu; Maqsood Alam; John Quale
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

5.  Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.

Authors:  Thomas P Lodise; Christopher D Miller; Jeffrey Graves; Jon P Furuno; Jessina C McGregor; Ben Lomaestro; Eileen Graffunder; Louise-Anne McNutt
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

6.  Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.

Authors:  Joseph B McPhee; Shawn Lewenza; Robert E W Hancock
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

7.  Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.

Authors:  Kaddy Barrow; Dong H Kwon
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

8.  Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes.

Authors:  C Y Wang; J S Jerng; K Y Chen; K Y Cheng; L N Lee; C J Yu; P R Hsueh; P C Yang
Journal:  Clin Microbiol Infect       Date:  2006-01       Impact factor: 8.067

Review 9.  Polymyxin antibiotics for gram-negative infections.

Authors:  Tamra M Arnold; Graeme N Forrest; Karen J Messmer
Journal:  Am J Health Syst Pharm       Date:  2007-04-15       Impact factor: 2.637

10.  Colistin and polymyxin B: a re-emergence.

Authors:  Sachin Gupta; Deepak Govil; Prem N Kakar; Om Prakash; Deep Arora; Shibani Das; Pradeep Govil; Ashima Malhotra
Journal:  Indian J Crit Care Med       Date:  2009 Apr-Jun
View more
  6 in total

1.  Genome-scale metabolic modeling of responses to polymyxins in Pseudomonas aeruginosa.

Authors:  Yan Zhu; Tobias Czauderna; Jinxin Zhao; Matthias Klapperstueck; Mohd Hafidz Mahamad Maifiah; Mei-Ling Han; Jing Lu; Björn Sommer; Tony Velkov; Trevor Lithgow; Jiangning Song; Falk Schreiber; Jian Li
Journal:  Gigascience       Date:  2018-04-01       Impact factor: 6.524

2.  Differential expression of two-component systems, pmrAB and phoPQ, with different growth phases of Klebsiella pneumoniae in the presence or absence of colistin.

Authors:  So Yeon Kim; Hyeon Jin Choi; Kwan Soo Ko
Journal:  Curr Microbiol       Date:  2014-03-01       Impact factor: 2.188

3.  Resistance and Heteroresistance to Colistin in Pseudomonas aeruginosa Isolates from Wenzhou, China.

Authors:  Jie Lin; Chunquan Xu; Renchi Fang; Jianming Cao; Xiucai Zhang; Yajie Zhao; Guofeng Dong; Yao Sun; Tieli Zhou
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 4.  Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria.

Authors:  Abiola O Olaitan; Serge Morand; Jean-Marc Rolain
Journal:  Front Microbiol       Date:  2014-11-26       Impact factor: 5.640

5.  Adaptive and Mutational Responses to Peptide Dendrimer Antimicrobials in Pseudomonas aeruginosa.

Authors:  Fatma Ben Jeddou; Léna Falconnet; Alexandre Luscher; Thissa Siriwardena; Jean-Louis Reymond; Christian van Delden; Thilo Köhler
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions.

Authors:  Nicholas Jochumsen; Rasmus L Marvig; Søren Damkiær; Rune Lyngklip Jensen; Wilhelm Paulander; Søren Molin; Lars Jelsbak; Anders Folkesson
Journal:  Nat Commun       Date:  2016-10-03       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.